Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk's oral GLP-1 treatment Wegovy, which has reached over 170,000 patients within four weeks of launch. (Source: Bloomberg)

Novo Nordisk CEO Mike Doustdar addresses concerns about the duration of the current slump in the company's legacy business due to price reductions and volume uptake dynamics. He highlights the strong initial uptake of the Wegovy pill, with 170,000 patients in four weeks, marking it as one of the most successful pharmaceutical launches in recent history. (Source: Bloomberg)